NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 48 filers reported holding NOVOCURE LTD in Q4 2015. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $21,131,000 | +93.9% | 2,691,801 | +110.9% | 0.00% | +100.0% |
| Q3 2016 | $10,899,000 | -21.7% | 1,276,265 | +7.0% | 0.00% | -33.3% |
| Q2 2016 | $13,914,000 | +389.1% | 1,192,298 | +506.8% | 0.00% | +200.0% |
| Q1 2016 | $2,845,000 | -38.4% | 196,485 | -4.9% | 0.00% | 0.0% |
| Q4 2015 | $4,618,000 | – | 206,546 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |